Dimerix (ASX: DXB) is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology called Receptor-HIT. Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using innovative receptor technology to identify and develop drugs in areas with an unmet need.
Dimerix comprises two entities, Dimerix Limited (ASX:DXB) and Dimerix Biosciences Pty Ltd (a wholly owned subsidiary of Dimerix Limited)
James Williams, Non-Executive Chairman
James is a Founder and Investment Director of Yuuwa Capital LP, a venture capital firm based in Western Australia and was the CEO of Dimerix between 2007 and 2009. Prior to establishing Yuuwa Capital and managing Dimerix, James was Managing Director of two medical device companies, ASX-listed Resonance Health Ltd and Argus Biomedical Pty Ltd, both of which took their products to market under his guidance. James also co-founded and is a former CSO and Director of iCeutica, Inc., a clinical stage nano drug reformulation company that was acquired in 2011. James is a Director of Yuuwa investee companies Adalta Pty Ltd, PolyActiva Pty Ltd and iCetana Pty Ltd. James is also a Director of Linear Clinical Research Ltd, a specialist early phase clinical trial unit, a member of the “Panel of Experts” for the University of Western Australia’s Pathfinder Fund and a member of the Federal Government’s Entrepreneur Program Committee. James completed his undergraduate degree in Biochemistry at the University of Aberdeen, PhD at Melbourne University and MBA at the University of Western Australia.
Nina Webster, Chief Executive Officer / Managing Director
Nina has over twenty five years of experience in the pharmaceutical industry, with leadership roles in investor relations, business development, and prosecution of intellectual property matters, as well as leading and managing the strategic, scientific and operational aspects of product development. Nina was formerly the Commercial Director for Acrux Limited (ASX: ACR), an Australian drug pharmaceutical company that has successfully developed and commercialised three products globally. Prior to Acrux, Nina was Director of Commercialisation and Intellectual Property for Immuron Limited (ASX: IMU), and previously spent 6 years in new product development with Wyeth Pharmaceuticals in the UK. Nina holds a Ph.D in Pharmaceutics from Cardiff University, a Bachelor degree in Pharmacology, a Masters degree in Intellectual Property Law from Melbourne University and an MBA from RMIT.
Sonia Poli, Non-Executive Director
Sonia is currently Executive Manager at AC Immune, a Nasdaq listed company, and has previously worked within Swiss Stock Exchange listed companies Hoffman la Roche and Addex Therapeutics, where she has held leadership and executive positions across various disciplines in drug discovery, pre-clinical development and translational science and has interacted with regulatory authorities, investors and public funding institutions. Sonia has held various corporate responsibilities such as outsourcing and out-licensing, and she has promoted academic collaborations and supported R&D collaborations with external partners.
Sonia is an accomplished R&D professional with 20 years international experience in large and small pharmaceutical companies. She has broad knowledge of small molecule drug design, optimisation and early clinical development, with expertise which encompasses multiple therapeutic areas.
Sonia is co-author of more than 50 scientific papers and several patents. Sonia holds a Masters degree and a PhD in industrial chemistry from Milan University (IT).
Hugh Alsop, Non-Executive Director
Hugh is an accomplished pharmaceutical and biotechnology executive with 20 years of experience in international business development, partnering, drug development and leadership of scientific teams. Hugh has demonstrated commercial management skills, profit accountability, and senior oversight of drug development programs for the international market. Hugh has a track record of being part of two significant exit transactions for the Australian life sciences industry, including two successful Phase 3 programs and two FDA approvals for Australian developed products.
Hugh’s most recent role was the Chief Executive Officer of Hatchtech Pty Ltd, where he helped secure a $200 million commercialisation agreement for its lead development product with global Indian pharmaceutical company Dr Reddy’s. In 2010, as Director of Business Development at Acrux Limited, Hugh was a key member of the team that licensed the testosterone product Axiron™, to global pharmaceutical company Eli Lilly for up to US$335m in potential milestones plus royalties.